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1. Introduction 
Increases in airway smooth muscle (ASM) mass characterize the pathology of patients who 
died of asthma. Recent studies also show that bronchial biopsies from individuals 
diagnosed with mild-to-moderate asthma also have increased ASM mass. As a consequence 
of such increases and the role of ASM in regulating bronchomotor tone, ASM plays a pivotal 
role in asthma pathophysiology. In the following review, we summarize the clinical and 
basic science evidence that suggests that ASM is a phenotypically distinct tissue whose 
therapeutic manipulation is critical for overall asthma management. 
1.1 ASM and airway mechanics 
In developed lungs, ASM modulates ventilation and perfusion dynamics and expedite 
clearing of foreign particulates from distal airways. As with other myocytes, ASM 
shortening is largely dependent upon Ca2+ homeostasis. Unlike cardiac and vascular 
myocytes, however, where membrane depolarization induces Ca2+ influx via voltage-
dependent Ca2+ channels, the pharmacological inability of Ca2+ channel blockers to affect 
bronchoconstriction implies a limited capacity of extracellular Ca2+ sources in regulating 
excitation-contraction coupling. This unique contractile property of ASM could be due to 
outward rectification that counteracts membrane depolarization. Such rectifying currents 
are mediated by the opening of large conductance Ca2+-activated and delayed rectifier K+ 
channels, responsible for repolarizing or hyperpolarizing ion fluxes imparting electrical 
stability to ASM (Parameswaran et al., 2002).  
Also integral to ASM are functional receptors for acetylcholine, cysteinyl leukotrienes, 
prostaglandins, thromboxanes, neurokinins, bradykinin, endothelin, thrombin and 
serotonin, whose pharmacological manipulation regulates airway contractile mechanics. 
Extracellular engagement of these receptors elicits intracellular inositol trisphosphate (IP3) 
and diacylglycerol (DAG)-mediated biphasic Ca2+ responses. Post-stimulus, the primary 
phase tension development is modulated by IP3R agonism at the sarcolemma, stimulating 
peak release of sarcoplasmic Ca2+ stores (Amrani, 2006; Deshpande & Penn, 2006). The 
secondary phase of tension is characterized by prolonged Ca2+ levels albeit lower than peak 
thresholds, regulated by PLC-ǃ1-mediated production of IP3 and DAG. The IP3-induced 
release of Ca2+ complexes with calmodulin (CaM) activates the enzymatic domain of myosin 
light chain kinase (MLCK), in turn phosphorylating the regulatory 20 kDa light chain 
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(MLC20) subunit of myosin. Sympathomimetics via cAMP/PKA-dependent mechanisms in 
part mitigate IP3R-mediated Ca2+ mobilization altering airway hyperresponsiveness (AHR). 
In addition, recent studies show that enhanced expression of MLCK in disease or upstream 
manipulation of its activity by therapeutic engagement of ǃ-adrenoceptor could also alter 
mediator-induced ASM contractility. Contractile agents such as acetylcholine (ACh) induce 
regenerative and propagative Ca2+ oscillations and airway narrowing. Once initiated in 
ASM cells, Ca2+ oscillations remain resistant to IP3R antagonists, as shown by the limited 
ability of heparin to suppress methacholine (MCh)-induced bronchoconstriction in 
individuals with asthma. Interestingly, agonist-induced Ca2+ oscillations can be inhibited by 
antagonists of the SR-resident ryanodine receptor (RyR), such as ryanodine and ruthenium 
red. These observations imply that Ca2+ release through RyR channels cooperates with IP3-
mediated Ca2+ mobilization to integrate the Ca2+ responses of ASM triggered by contractile 
agonists. Mechanistic studies show that RyR channel-dependent Ca2+ oscillations are 
regulated by CD38, a cyclic ADP ribose hydrolase that catalyzes the conversion of ǃ-NAD to 
cADPR (Jude et al., 2008). Formation of cADPR and its interactions with several accessory 
proteins including tacrolimus (FK506)-binding protein modulate RyR-mediated Ca2+ 
kinetics. Similarly, cADPR could stimulate CaM-mediated mechanisms leading to Ca2+-
induced Ca2+ release, enhancing the overall propagation of Ca2+ oscillations throughout the 
cytosol. Several extracellular stimuli enhance CD38 expression and cADPR generation in 
human ASM; however, the precise mechanism by which extracellular cADPR is shunted to 
Ca2+ intracellular stores remains unknown (Bara et al., 2010). 
1.2 ASM as a structural cell immunomodulator 
Cytokine secretions of CD4+ Th2 subtypes play a pivotal role in integrating inflammation and 
hypercontractile responses in airways of individuals with asthma. Studies in sensitized knock-
out or transgenic murine models illustrate Th2 cytokine prominence in regulating abnormal 
airway physiology. As structural and spatially organized tissue throughout the airways, ASM 
cells serve as effector cells for most cytokines. After cytokine stimulation, ASM alters pro-
inflammatory gene expression in an autocrine-paracrine manner promoting inflammatory 
processes within airways (Damera et al., 2009b). In isolated ASM tissue, IL-4 or IL-13 
stimulates eotaxin that is inhibited by anti-IL-4Rǂ antibodies and antisense oligonucleotides to 
STAT-6 (Hirst et al., 2002; Peng et al., 2004). Based on the demonstrated ability of several 
disease-specific mediators including tumor necrosis factor alpha (TNFǂ), IL-1ǃ, transforming 
growth factor beta (TGFǃ), thymic stromal lymphopoietin (TSLP), IL-17A, endothelin-1 and 
sphingosine-1-phosphate (S-1-P) to induce IL-6 secretion in ASM, airway myocytes may 
directly contribute to IL-6 production in asthma (Ammit et al., 2001; Iwata et al., 2009; McKay 
& Sharma, 2002; Shan et al., 2010; Tliba & Panettieri, 2009). Pharmacological inhibition of 
cellular ligand for herpes virus entry mediator and lymphotoxin receptor (LIGHT), a leukocyte 
expressed member of TNF family, reduces allergen-induced lung fibrosis, smooth muscle 
hyperplasia, cytokine levels (IL-13) and AHR in murine models of chronic asthma, despite 
having little effect on airway eosinophilia (Doherty et al., 2011). In a more complex role, TNFǂ 
induces interferon beta (IFNǃ) secretion from ASM which, by its autocrine actions, alters 
TNFǂ-mediated IL-6 and regulated upon activation, normal T cell expressed and secreted 
(RANTES) secretion (Tliba et al., 2003). ASM in spatial proximity to epithelium also selectively 
enhances basal or TNFǂ-induced IL-6 and IP-10 secretion, with little effect on fractalkine levels 
(Damera et al., 2009c). Despite the lack of a membrane-adherent IL-6R in ASM, IL-6 induces 
eotaxin secretion via a soluble IL-6R (sIL-6R ) receptor (Ammit et al., 2007). Evolving evidence 
also shows that conditioned serum from ASM cells treated with a combination of TNFǂ, IL-1ǃ 
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and IFNǄ advances an eosinophilopoietic potential on CD34+ bone marrow-derived cells, a 
phenomenon ablated by neutralizing antibodies to IL-5 and granulocyte-macrophage colony-
stimulating factor (GM-CSF) (Fanat et al., 2009). Modulating eosinophil activation and 
survival, ASM cells secrete GM-CSF in response to TNFǂ/IL-1ǃ alone or in combination with 
serum, or mast cell-derived tryptase. Endothelin (ET-1) and TNFǂ also elicit GM-CSF and ET-1 
secretion via an intricate mechanism sensitive to bosentan and specific inhibition of ET-R 
(Knobloch et al., 2009). Another constituent member of the IL-6 superfamily, oncostatin M 
(OSM), enhances IL-1R1 abundance and augments IL-1ǃ-mediated VEGF, monocyte 
chemotactic protein-1 (MCP-1) and IL-6 secretion, or synergizes with IL-13 to augment 
eotaxin-1 expression in airway myocytes (Faffe et al., 2005a; Faffe et al., 2005b) as summarized 
in Table 1.  
 
Mediator in Asthma In Vitro Biopsies Function 
Cytokines    
IL-6 Yes Yes Inflammation 
IL-33 Yes Yes Inflammation 
CX3CL-1   Yes Mast cell chemotaxis 
CCL-11  Yes  Eosinophil chemoattractant 
CXCL-8  Yes  Neutrophil chemotaxis 
CXCL-10  Yes Yes Mast cell chemotaxis 
    
Peptide growth factors    
TGF-ǃ1, LAP  Yes ASM hyperplasia 
    
Adhesion molecules    
CD51, CD44 Yes  Cell-ECM interactions 
CD40, OX40, CD54  Yes  Cell-cell interaction 
Integrin alpha(5) Yes  ECM deposition 
CD106   Yes Leukocyte ligand 
    
ECM components    
Collagen type I ǂ1 Yes  Airway remodeling 
Perlecan Yes  Airway remodeling  
Collagen III Yes Yes Airway remodeling  
Fibronectin Yes  Airway remodeling  
    
Transcription factors    
mtTFA, NRF-1, PGC-1 ǂ Yes  Mitochondrial biogenesis 
    
Receptors    
E-prostanoid receptor 2/ 3 Yes  ASM hyperplasia 
    
Proteases    
ADAM-33  Yes Cell-matrix interaction 
Table 1. Mediators expressed by airway myocytes from asthmatics in vitro and in  
biopsies. References are included within the text. 
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In individuals with severe asthma, airway neutrophil abundance correlates with enhanced 
CXCL-8 levels. Enhanced CXCL-8 in supernatants from ASM cultures activates CXCR-1 
receptors and promotes mast cell trafficking. An increase in CXCL-8 secretion can also 
increase binding of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), 
CCAAT/enhancer-binding protein beta (C/EBPǃ), and RNA polymerase 2 (RNA Pol II) 
transcriptional elements to CXCL-8 promoter (John et al., 2009) in ASM cells. Human ASM 
cells secrete IL-8 when treated exogenously with IL-1ǃ, TNFǂ, or TGFǃ (Chung, 2000). 
Likewise, phenotypic changes in ASM have been suggested to augment IL-8-dependent 
AHR and to enhance IgE-mediated IL-4 and IL-6 levels from ASM cells (Govindaraju et al., 
2006; Govindaraju et al., 2008). Evoking a COPD-relevant phenotype, pro-inflammatory 
stimuli, such as TNFǂ and cigarette smoke, also synergize to induce IL-8 secretion from 
ASM (Oltmanns et al., 2005). Despite minimal effect in directly mediating ASM-derived 
cytokine secretion, IL-9 augments TNFǂ-induced IL-8- or IL-13-induced eotaxin secretion in 
cultured ASM cells (Baraldo et al., 2003). Further, IL-9 selectively and directly enhances 
eotaxin-1/CCL11 secretion that can promote airway eosinophilia (Yamasaki et al., 2010). 
Leukocyte migration and retention, primarily regulated by selectins on endothelial cells, are 
subsequently mediated by timely expression of cell adhesion molecules (CAMs) on 
“primed” airway structural cells as shown in Figure 1. 
Studies in vitro and in vivo show that expression of CAMs mediates cell-cell interactions 
during inflammation and tissue remodeling (Kelly et al., 2007). Expectedly, disease-relevant 
components such as cytokines, bacterial endotoxins and viral proteins enhance ASM 
resident intercellular adhesion molecule-1 (ICAM-1) expression (Tliba et al., 2008a). 
Cytokines including TNFǂ and IL-1ǃ induce ICAM-1 and vascular cell adhesion molecule-1 
(VCAM-1) in ASM via diverse signaling pathways enhancing localized inflammation. 
Others show that using blocking antibodies against ICAM-1 and VCAM-1 on ASM cells or 
activated T cell resident lymphocyte function-associated antigen 1 (LFA-1) and very late 
antigen-4 (VLA-4) greatly attenuated T cell adherence to ASM as compared to either anti-
ICAM or anti-VCAM alone (Duplaa et al., 1997). Further, anti-CD44 antibodies (Abs) in 
combination with monoclonal Abs (mAbs) against LFA-1 and VLA-4 synergistically reduce 
the binding of activated T cells to the level observed for resting T cells (Lazaar et al., 1994). 
CAM expression could mediate T cell adherence to airways and alter airway 
bronchoconstriction and bronchodilation responses (Hakonarson et al., 2001; Hughes et al., 
2000). In cultured ASM cells, the engagement of adhesion and immune receptors such as 
CD40, CD44 and VCAM-1 leads to signaling events that may be involved in proliferative 
responses (Lazaar et al., 1998). After successive antigen challenges, adoptive transfer of 
CD4+ T cells from sensitized rats induces proliferation and attenuates apoptosis of ASM in 
naive recipients. Concomitantly, modified CD4+ T cells expressing enhanced green 
fluorescent protein (GFP) were localized in juxtaposition to ASM cells conferring that cell-
cell interaction participates in airway remodeling. In children or adults with asthma, 
respiratory viruses frequently trigger exacerbations of asthma symptoms. Empirical studies 
now show that replication-independent rhinovirus-15 (RV-15) induces ASM-derived IL-5 
and IL-1ǃ secretion via ASM-resident ICAM-1 molecules (Grunstein et al., 2001; Oliver et al., 
2006). Expanding the role of CAMs in T lymphocyte trafficking, anti-ICAM-1 or anti-
VCAM-1 depletes eosinophil and neutrophil adherence to ASM. Besides immune cells, mast 
cell infiltration of ASM tissue occurs via expression of a heterophilic adhesion molecule, 
tumor suppressor in lung cancer-1 (TSLC-1) (Yang et al., 2006). In an expanding role for 
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CAMs in airway inflammation, studies also determined a critical role for a ǃ-galactoside-
binding lectin, Galectin-3 (Gal-3), in eosinophil trafficking and recruitment (Ramos-Barbon 
et al., 2005). As compared to allergen-induced responses in Gal-3+/+ mice, Gal-3–/– mice have 
altered CAM expression, lower AHR and Th2 responses (Zuberi et al., 2004). 
 
Fig. 1. Phenotypic modulation of airway smooth muscle (ASM) in asthma. Environmental 
stimuli induce chronic alterations in ASM characterized by hypertrophy and hyperplasia. 
Additionally, cytokines and growth factors modulate agonist-induced shortening of ASM 
that promotes airway hyperresponsiveness (AHR). Over time, ASM mass increases often in 
concert with extracellular matrix (ECM) deposition. The physiologic relevance of the 
increased ASM mass may relate to irreversible airflow obstruction. ASM also interacts 
directly with trafficking leukocytes and with mast cells and indirectly through the secretion 
of chemokines and cytokines. CAMs: cell adhesion molecules; GPCRs: G protein coupled 
receptors; RTKs: receptor tyrosine kinases 
1.3 ASM phenotype switching 
While increased ASM mass is a constitutive characteristic of remodeling in asthma, 
convincing studies by Ebina et al show that ASM mass increases are both physiologically 
discontinuous and subtype specific (Ebina et al., 1993). For instance, in some subjects with 
asthma, ASM mass was increased only in the central bronchi compared with others who 
manifested enhanced muscle thickness throughout the bronchi. In addition the number of 
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smooth muscle nuclei in the central airways was increased, indicating the presence of ASM 
hyperplasia. In patients with increased mass throughout the bronchi, ASM cell volume was 
significantly increased, signifying ASM hypertrophy (Wenzel et al., 1999). Accordingly, 
examination of biopsies from patients with mild asthma shows significant increases in ASM 
numbers, with minimal alterations in cellular morphometry. Indeed, studies addressing the 
molecular mechanism inducing ASM mass in animals have convincingly shown that allergic 
sensitization enhances ASM mass. In murine models, ovalbumin (OVA)-induced 
sensitization and challenge promotes thickening of the peribronchial smooth muscle layer. 
Similarly, in guinea pigs, allergen challenge induces bromodeoxyuridine uptake into ASM 
layers, implying enhanced mitogenesis. Likewise, bronchoalveolar lavage (BAL) fluid 
derived from individuals with asthma enhances DNA synthesis and ASM cell numbers 
(Naureckas et al., 1999), implying that BAL soluble constituents likely promote ASM 
hyperplasia. Post-allergen challenge, quantitative increases in cytokines, enzymes including 
tryptases and matrix metalloproteinase (MMPs) and growth factors define airway pathology 
in animal studies; however, contradictory empirical outcomes limit the mitogenic potential 
of BAL cytokines. More prominent are the effects of airway-localized growth factors in 
stimulating ASM growth via the RTK-PI3K axis. Among asthma-relevant outcomes such as 
tissue maturation and epithelial mucin (MUC) gene expression, peptides that stimulate 
receptors for epidermal growth factor (EGF), insulin-like growth factors (IGFs), platelet-
derived growth factor (PDGF), and fibroblast growth factor (FGF)-2 also induce ASM 
proliferation (Marwick et al., 2010). 
Selected contractile agents such as histamine, ET-1, substance P, 5-HT, ǂ-thrombin, 
thromboxane A2 and LTD4 also enhance ASM mitogenesis (Dekkers et al., 2009; Lazaar & 
Panettieri, 2005). Studies suggest that mediator-induced ASM proliferation is regulated by 
cell cycle proteins as surrogate markers of mitogenesis. While BAL fluid derived from 
subjects with asthma mediates ERK-mediated DNA synthesis in ASM, such responses are 
associated with increased cyclin D1 protein (Naureckas et al., 1999). Besides ERK, 
pharmacological inhibitors of PI3K also diminish cyclin D1 protein expression and DNA 
synthesis in ASM. Other studies identified two nuclear antigens, Ki67 and proliferating cell 
associated nuclear antigen (PCNA), as potential markers of proliferation. Investigators 
suggest that despite comparable mitogen-induced induction of PI3K-AKT axis, ASM 
proliferation results from diminished cell cycle inhibitory proteins such as C/EBPa 
elements. Others have shown that ASM proliferation is induced by overexpression of Src or 
PI3K alone, and inhibition of PI3K abrogated mitogen-induced ASM proliferation. 
Downstream PI3K stimulates S6K1-mediated translation of cell cycle proteins via 
rapamycin-sensitive events (Scott et al., 1996). Importantly, sustained activation of PI3K and 
S6K1 at 12h discriminated ASM mitogens from non-mitogenic agonists that otherwise 
equally potentiate ERK1/2 at 1h (Krymskaya et al., 2000). Similar upstream pathways also 
induce ASM hypertrophy via mammalian target of rapamycin (mTOR), 4E-binding protein 
(4E-BP), the transcription factor eIF4E and S6 kinase or the inhibition of glycogen synthase 
kinase (GSK)-3ǃ (Bara et al., 2010; Berger et al., 2005) 
Myofibroblasts are ǂ-smooth actin-positive mesenchymal precursors that transiently 
undergo reversible phenotypic differentiation to/from a variety of resident structural 
populations including ASM cells (Begueret et al., 2007; Brewster et al., 1990; Gizycki et al., 
1997). These cells may migrate and differentiate into resident populations within ASM 
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bundles, thus mediating hyperplasia. In support of this phenomenon, studies show that 
bone marrow-derived, CD34+-Collagen-1+-ǂ-SMA+ circulating fibrocytes migrate towards 
ASM bundles during inflammatory challenge. Post allergen challenge, increased presence of 
myofibroblasts in the submucosa has led some to postulate that ASM cells could migrate 
from airway bundles towards epithelium, explaining diminished space between smooth 
muscle and epithelium in asthmatic airways. Varied mediators including PDGF, TGF-ǃ and 
chemokines such as CCL-11 and CXCL-8 induce chemotaxis of ASM cells in vitro 
(Govindaraju et al., 2006; Hirst et al., 2004; Ito et al., 2009; Joubert & Hamid, 2005; Mukhina 
et al., 2000). Similarly, migration of ASM in vitro could be enhanced by coating with 
collagens III and V and fibronectin as compared with collagen I, elastin and laminin 
(Bullimore et al., 2011), implying that disease-specific matrix alteration could also mitigate 
this process. In line with in vitro studies, Thomson and Schellenberg hypothesized that the 
presence of collagen deposition in and around ASM bundles may contribute to the overall 
increase in the ASM content (Thomson & Schellenberg, 1998). 
The overall functional impact of enhanced ASM mass on asthma symptoms including AHR 
seems heterogeneous and remains unclear. During proliferation, ASM cells likely manifest a 
phenotypic switch characterized by compromised contractile characteristics as shown after 
mitogen treatment or cultured on diverse ECM (Dekkers et al., 2007; Halayko et al., 2008; 
Halayko et al., 2006). Predictably, such alterations correlate with quantitative increases in 
synthetic pathways for protein and lipids and mitochondrial function with a diminished 
abundance of contractile proteins. Compared to specific proteins that mark pro-contractile 
characteristics, such as smooth muscle myosin heavy chain, SM22, calponin and smooth 
muscle ǂ-actin, proliferating ASM shows increased non-muscle myosin heavy chain (MHC), 
caldesmon, vimentin, ǂ/ǃ-protein kinase C (PKC) and CD44 homing cellular adhesion 
molecule (Halayko et al., 2008; Hirota et al., 2009). Others appreciate the expression and 
accumulation of dystrophin glycoprotein complex (DGC), a multimeric sarcolemma 
complex that regulates caveoli organization, with altered ASM contractility (Sharma et al., 
2008). 
2. Is ASM different in asthma? 
2.1 ASM mass and airway remodeling 
Using anatomically matched bronchial samples derived from inflated lungs, Hossain and 
Heard show that thickness of ASM is enhanced in patients with fatal asthma (Hossain & 
Heard, 1970). Pursuing alternate procedures to inflate lungs via pulmonary vasculature, 
Dunnill et al. show that increased ASM mass accounts for 11.4 ± 3.4% of wall thickness in 
asthmatic airways, as compared to 4.6 ± 2.2% in normal airways (Dunnill et al., 1969).  
Others explain that expression of ǂ-smooth muscle actin and myosin light-chain kinase 
negatively correlates with prebronchodilator and postbronchodilator FEV1 values in patients 
with severe asthma (Benayoun et al., 2003). Similarly, quantitative structural analysis of 
peripheral airways showed that, in addition to increased luminal occlusion and immune cell 
infiltrates, bronchioles of subjects with fatal asthma showed enhanced smooth muscle 
presence (Saetta et al., 1991). In addition to acknowledged effects in fatal asthma, 
discontinuous increases in ASM numbers distinguish airway physiology within asthma 
subtypes (Ebina et al., 1993). Owing to challenges in obtaining biopsies that encompass the 
full thickness of ASM, few studies could define growth of ASM in patients with non-fatal 
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asthma. In studies by Carroll et al, analysis of similarly identified central airways samples 
from inflated lungs of all asthma severities showed that the area of smooth muscle in large 
bronchioles was greater in fatal and non-fatal cases than in control cases, but there were no 
differences between fatal and non-fatal cases of asthma (Carroll et al., 1993). Accordingly, 
comprehensive evaluation of endobronchial biopsies by quantitative morphometry, laser 
capture microdissection, and RT-PCR also shows a two-fold increase in ASM numbers in 
individuals with mild asthma. These studies concluded that ASM hyperplasia and not 
hypertrophy is a pathologic characteristic in airways of individuals with mild-to-moderate 
asthma, and that gene expression of contractile proteins considered markers of a 
hypercontractile phenotype are not increased across asthma populations (Woodruff et al., 
2004). Studying ASM growth in steroid-resistant asthmatics, Pegorier et al report that 
epithelium resident endothelin (EDN1) and IL-8/CXCL8 levels negatively correlate with pre 
and postbronchodilator FEV1 values, and positively relate to ASM area and thickness of 
subepithelial basement membrane (Pegorier et al., 2007). 
2.2 ASM function and AHR 
Since airway smooth muscle (ASM) is the pivotal effector tissue controlling bronchomotor 
tone, it is suggested that ASM dysfunction contributes directly towards AHR in asthma. 
Mutually distinct lines of evidence show that increases in the shortening velocity of ASM 
could mediate AHR (Antonissen et al., 1979; Mitchell et al., 1993; Seow et al., 1998; Solway & 
Fredberg, 1997). Following induced bronchoconstriction, deep inspiration causes airways of 
both normal and asthmatic individuals to dilate transiently; yet, the subsequent 
reconstriction is more prompt in asthmatics (Jackson et al., 2004; Jensen et al., 2001; 
Pellegrino et al., 1996). Empirical evidence in vitro shows that bronchial ASM cells from 
asthmatic patients have increased shortening velocity relative to controls (Ma et al., 2002). 
Likewise animal models of innate and allergic AHR manifest enhanced ASM shortening 
(Bullimore et al., 2011). Such increase in muscle-shortening velocity may be due to 
augmented MLCK activity in asthmatic ASM (Ammit et al., 2000). Concurrently, others 
propose that altered cytosolic calcium handling within ASM could induce AHR in ASM 
from subjects with asthma (Janssen, 1998). Indeed, ASM [Ca2+]i levels are greater in 
hyperresponsive Fisher rats as compared to less responsive Lewis rats (Tao et al., 1999). 
Since diverse excitatory stimuli, such as leukotrienes, acetylcholine, ozone, acroleins and 
cytokines, provoke AHR by mobilizing cytoplasmic calcium concentration, it is conceivable 
that the calcium handling in the smooth muscle per se is altered (Parameswaran et al., 2002). 
ASM contractility is hormone-responsive, leading some to focus on gender disparities in 
asthma epidemiology. Preliminary studies now suggest that oxytocin levels are enhanced in 
BAL fluid from asthmatic individuals and that selected cytokines (IL-13) amplify oxytocin's 
effects by increasing the expression of functional oxytocin receptor within ASM (Amrani et 
al., 2010). 
As with TNFǂ and IL-13, pro-inflammatory cytokines modulate intracellular Ca2+ responses 
and AHR via expression of CD38. Compared to CD38−/− mice, airway myocytes isolated 
from wild-type mice exhibit higher agonist-induced intracellular Ca2+ responses in vitro 
while CD38+/+ mice develop a higher magnitude of AHR after allergen challenge (Gally et 
al., 2009; Guedes et al., 2008; Guedes et al., 2006). Later studies in human ASM imply that 
differential expression of CD38 by heightened induction of common signaling cascades 
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likely mediates AHR in asthma (Jude et al., 2010). Clinical evidence shows that ASM derived 
from subjects who died of asthma has enhanced immunoreactivity to receptors for receptor 
tyrosine kinases (RTKs) and that such increases correlate with disease severity (Chanez et 
al., 1995; Perkett, 1995; Polosa et al., 2002; Puddicombe et al., 2000; Yamanaka et al., 2001). 
Increased expression of EGFR and PDGFR ligands can be triggered by factors that modulate 
asthma etiology including allergens, pro-inflammatory cytokines, environmental tobacco 
smoke, and virus infection (Ingram & Bonner, 2006; Le Cras et al., 2011). Expectedly, EGFR 
ligands are elevated in samples from asthmatic airways, and mechanistic studies show that 
EGFR activation elicits augmented mitogenic responses in asthmatic ASM (Amishima et al., 
1998). Such proliferative responses are accompanied by inhibition of cyclic AMP (cAMP) 
effectors such as protein kinase A (PKA) and exchange protein directly activated by cAMP 
(Epac), entailing a phenotypic switch characterized by diminished expression of contractile 
proteins including smooth muscle actin, myosin and calponin (Roscioni et al., 2011). As seen 
in biopsies of severe asthmatics, empirical studies show that ASM mitogens enhanced 
expression of defined GTPase-accelerating proteins (GAPs) called RGS (Damera et al., 2010). 
Given the ability to interact with Gǂ subunits of GPCR and p85ǂ-PI3K, expression of RGS 
molecules could induce a hypocontractile and hyperproliferative ASM phenotype 
reminiscent of severe asthma (Bansal et al., 2008; Liang et al., 2009). 
2.3 ASM markers of chronic inflammation 
As repeatedly illustrated by mechanistic studies in vitro, ASM-expressed cytokines, peptide 
growth factors, ECM proteins and adhesion molecules extensively regulate airway 
pathology (Damera et al., 2009b; Tliba & Panettieri, 2008). Predictably, bronchial biopsies 
from asthmatic individuals show a greater role of ASM in inflammation and remodeling; 
however, the ability of isolated ASM cells to retain this phenotype in culture has led some to 
propose a genetic etiology. Although functionally ambiguous, a disintegrin and 
metalloproteinase-33 (ADAM-33), a member of zinc-dependent metalloproteases, is 
associated with AHR and diminished lung function in asthma (Foley et al., 2007). 
Expression of active chemotactic factors by ASM promotes adherence and retention of 
circulating T cells and mast cells to airways. Recruitment and retention of T cells and mast 
cells to ASM are dependent on expression of functionally active chemotactic factors. For-
instance, in airways of individuals with asthma, enhanced mast cell presence within ASM 
layers correlates with augmented expression of TGFǃ1. Among other triggers, stimulation of 
ASM resident protease activated receptor 2 (PAR-2) by mast cell-derived tryptase enhances 
TGFǃ1 expression, thus potentiating a “feed forward system” leading to increased mast cell 
recruitment (Berger et al., 2003). In addition, as demonstrated in vitro, TGFǃ1 facilitates 
transformation of epithelial cells to myofibroblasts, with likely consequences to ASM 
hyperplasia (Zuyderduyn et al., 2008). With inflammation, expression of mast cell resident 
CD44 (hyaluronate receptor) and CD51 (vitronectin receptor) to ECM defines mast cell 
adhesion to ASM. As compared to normal cells, such interactions are enhanced in cultures 
derived from asthmatic airways (Girodet et al., 2010). Likewise, cytokines differentially alter 
expression of co-stimulatory ligands such as CD40 and OX40 among ASM from airways of 
normal and asthmatic individuals, implying that disease pertinent mechanisms intrinsic to 
ASM mitigate enhanced leukocyte adherence in asthma (Burgess et al., 2005). Besides cell 
adherent factors, marked increases in soluble chemotactic mediators such as IL-33, CX3CL-1 
and CXCL-10 are seen in ASM tissue within bronchial biopsies in asthma (Brightling et al., 
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2005; El-Shazly et al., 2006; Prefontaine et al., 2009). While CXCL-10-mediated activation of 
mast cell resident CXCR-3 predicts ASM microlocalization, CXCL-10 is preferentially 
expressed in bronchial biopsies and ex vivo cells from individuals compared with those from 
healthy control subjects. As a promoter of Th2 immunity, TNFǂ-mediated IL-33 secretions 
are refractory to corticosteroid effects (Prefontaine et al., 2009). Further, immune 
histochemical (IHC) analysis of bronchial biopsies shows increased IL-33 localization within 
ASM bundles of subjects with mild-to-moderate asthma, implying a likely role in 
pathogenesis of asthma. During RV-induced asthma exacerbation, cytokine secretion such 
as IL-6 is transcriptionally triggered by specific innate immune responses. Interestingly, 
such responses are differentially regulated in ASM derived from asthmatic and normal 
individuals (Oliver et al., 2006). As with COPD, an increase in neutrophilic inflammation 
correlates with CXCL-8 secretion in airways of severe asthmatics. Mechanistic studies by 
John et al imply that augmented binding of NF-κB, C/EBPǃ and RNA Pol II elements to 
CXCL-8 promoter likely mediates CXCL-8 increases within asthmatic ASM (John et al., 2009) 
as shown in Table 1. 
2.4 ASM and disease matrix 
As compared to healthy individuals, ASM cells from patients with asthma secrete increased 
amounts of collagen I and perlecan but reduced amounts of collagen IV, chondroitin sulfate, 
laminin ǂ1 and hyaluronan (Johnson et al., 2004; Klagas et al., 2009). While TGFǃ1 and 
connective tissue growth factor (CTGF) enhance collagen I and fibronectin production in 
normal and asthmatic ASM, differences in intrinsic signaling mechanisms likely alter ECM 
deposition in asthma (Burgess et al., 2003; Johnson et al., 2006). In asthma, mast cell 
localization to ASM bundles promotes mutual phenotypic changes that promote 
development of AHR (Kaur et al., 2010). For instance, in co-cultures IgE-independent mast 
cell release of ǃ-tryptase augments ǂ-SMA within ASM via autocrine actions of TGFǃ. 
Despite minimal effects on mast cells, TGFǃ enhances ASM-derived ECM proteins such as 
fibronectin which modulate mast cell activation and transition to a myofibroblast phenotype 
(Chan et al., 2006; Johnson et al., 2006; Lam et al., 2003; Moir et al., 2008; Peng et al., 2005; 
Swieter et al., 1993). This altered mast cell phenotype has the potential to evoke an ASM 
contractile phenotype, further propagating AHR. Rhinovirus infection differentially alters 
ECM components such as fibronectin and collagen 4 in asthmatic ASM, thus facilitating 
increased cell migration and remodeling at sites of  infection (Kuo et al., 2011). Others 
speculate that asthma pertinent ECM dysregulation likely involves imbalances in ECM 
modifying MMP or their endogenous enzyme inhibitors called tissue inhibitors of matrix 
metalloproteinases (TIMP). Supported by studies using histopathological assessment, 
investigators showed increased MMP-9 and -12 within ASM layers in fatal asthma (Araujo 
et al., 2008). Comparative assessment of BAL fluid of patients undergoing mechanical 
ventilation in severe asthma and those with mild etiology shows enhanced MMP-3 and -9 
levels in severe disease subtypes (Lemjabbar et al., 1999). Others propose that minor allelic 
single-nucleotide polymorphisms in the MMP-12 gene could affect FEV1 among children 
with asthma (Hunninghake et al., 2009). Besides associating rs652438, a common gene 
variant of MMP-12, with disease severity in young asthmatic individuals, Mukhopadhyay et 
al show that pharmacologic inhibition of MMP-12 downregulates allergen-induced airway 
responses (Mukhopadhyay et al., 2010). In comparison to corticosteroid-treated asthmatics 
or healthy individuals, BAL resident TIMP-1 is increased in untreated asthma, implying that 
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a potential MMP/TIMP imbalance could also orchestrate a pro-asthmatic phenotype 
(Mautino et al., 1999a; Mautino et al., 1999b).  
ASM function is also modulated by (i) epithelial cell-derived mediator secretion post-viral 
infections or (ii) air pollutants due to loss of epithelial barrier function. (Chanez, 2005). Viral 
infections induce epithelial cell secretion such as IFNǃ which inhibits ASM proliferation, 
shortening or pharmacological efficacy of anti-inflammatory agents (Banerjee et al., 2008; 
Tliba et al., 2008b). Similarly, destruction of the epithelium elicits altered ASM responses to 
environmental pollutants such as ozone, as demonstrated using co-culture (Damera et al., 
2009c). Epithelium also expresses mediators such as prostanoids, leukotrienes, cytokines 
and nitric oxide which mitigate airway bronchomotor tone (Chitano, 2011). Furthermore, 
epithelium-derived enzymes such as acetylcholinesterase, N-methyltransferase, angiotensin-
converting enzyme and neutral endopeptidase regulate neural transmission within airways 
(Knight & Holgate, 2003; Spina, 1998). Studies show that post RV infections, epithelium 
mediates desensitization of the ǃ2-adrenergic receptor on ASM (Trian et al., 2010). Upon 
injury, bronchial epithelium modulates myocyte proliferation through MMP-9 secretions or 
via growth factors (Malavia et al., 2009). 
2.5 Asthma and ASM: Altered cell signaling 
As mainstay therapy in asthma, glucocorticoids suppress inflammation by complex 
interactions involving their cognate nuclear receptors, glucocorticoid receptors (GR). 
Although studies correlate impairment in GR expression or mutations in genes encoding 
these receptors to asthma, no evidence exists on the direct contributory function of these 
receptors to asthma (Adcock et al., 1996; Corrigan et al., 1991; Lane et al., 1994). While most 
pharmacological effects elicited by glucocorticoids involve GR-activation, downstream 
signaling divergence is illustrated by studies where glucocorticoids diminish serum-
stimulated IL-6, yet fail to alter proliferative responses in cells from individuals with 
asthma. Despite comparable levels of GR in ASM derived from asthma patients, decreased 
levels of co-transcription factor C/EBPǂ may diminish transcription of glucocorticoid-
induced anti-proliferative protein p21(Waf1/Cip1). Compensatory induction of C/EBPǂ by 
transfection of ASM from subjects with asthma restores antiproliferative effects of 
glucocorticoids (Roth et al., 2004). Similarly, Damera et al suggest that inhibiting mitogen-
induced phosphorylation of retinoblastoma protein (Rb) and Chk1 proteins by calcitriol 
inhibits ASM growth in a corticosteroid-independent manner (Damera et al., 2009a). In 
ASM, TGFǃ induces PI3K-mediated release of VEGF and IL-6 which in turn modulates cell 
proliferation and angiogenesis (Johnson et al., 2006; Shin et al., 2009). As compared to 
asthmatic ASM, specific inhibition of p110 ǃ isoform of PI3K alone differentially attenuates 
TGFǃ-mediated secretion in normal tissue, implying an altered role of PI3K isoforms in 
asthma (Moir et al., 2011). While mitogens induce proliferation via ERK and PI3K in normal 
ASM, intrinsic abnormalities in expression of the endogenous ERK inhibitor, MKP-1, 
promote predominance of the PI3K proliferative pathway within ASM from individuals 
with asthma (Burgess et al., 2008). Studies by John et al suggest that increased binding of 
transcription factors such as NF-κB, C/EBPǃ and RNA Pol II to the CXCL-8 promoter 
modulates pro-inflammatory outcomes in asthmatic ASM (John et al., 2009). Multiple 
stimuli that modulate inflammation, proliferation and asthma also activate NF-κB 
transcription factors, and disruption of NF-κB activation through expression of a super-
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repressor form of IKBǂ substantially impairs proliferation (Brar et al., 2002; Clarke et al., 
2009; Damera et al., 2009b). Explaining increased mitochondrial mass and oxygen 
consumption in asthmatic ASM, Trian et al show differences in mitochondrial biogenesis 
and expression of transcription factors such as peroxisome proliferator-activated receptor Ǆ 
co-activator (PGC)-1ǂ, nuclear respiratory factor-1 (NRF-1) and mitochondrial transcription 
factor A (mtTFA) in ASM derived from asthma, COPD and normal populations (Trian et al., 
2007). 
3. Summary and future directions 
Although asthma pathophysiology represents the complex interactions among structural 
and trafficking cell populations, this summary identifies factors and signaling events within 
ASM that promote an asthma phenotype. Evidence supports that altered cell function in 
cultured ASM derived from individuals with asthma exists and supports the hypothesis that 
an intrinsic ASM phenotype likely occurs in asthma. With this insight, focusing on the 
development of new pharmacological approaches that target ASM may offer unique 
approaches in asthma therapy. 
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